Paytm's Vijay Shekhar Sharma Sides With Piyush Goyal On India Vs China Debate
Commerce Minister Piyush Goyal's remarks at Startup Mahakumbh 2025 on Thursday triggered a heated debate online. After Zepto CEO Aadit Palicha, Ashneer Grover, and former Infosys CFO Mohandas Pai, Paytm founder Vijay Shekhar Sharma too shared his thoughts on the issue.
Commenting on the India versus China dialogue Goyal sparked, Sharma said that developed ecosystems like China are able to play longer haul.
"China was much ahead in terms of electric vehicles," Sharma said during an event at the Startup Mahakumbh. "India is new, we are playing what's in front of us."
He said that in India, current opportunities being tapped to generate enough funds to support long-term growth stories.
Goyal, while comparing India's startup ecosystem to China's, had questioned, "Should we aspire to be, or are we going to be happy being delivery boys and girls?"
His remarks were aimed at India turning into a hotspot for the consumer startup sector, in which Swiggy, Zomato and Zepto are key players.
Earlier in the day, Zepto's Aadit Palicha posted on X, saying India lags in technological revolutions due to the unavailability of strong internet companies.
Palicha also highlighted that consumer startups have significantly impacted the Indian economy by creating thousands of jobs through taxes and building enhanced supply chain networks. He argued that India lacks large-scale foundational AI models because it hasn't yet built strong internet companies.
Mohandas Pai also hit back at Piyush Goyal, when he tweeted, "Minister Piyush Goyal there are very many small deep tech start-ups in Chip design, IOT, Robotics, EV charging, BMS in India, growing rapidly but where is the capital?"
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.